Your browser does not support javascript:   Search for gard hereSearch for news-and-events here.

Diseases

Genetic and Rare Diseases Information Center (GARD)

Print friendly version

Respiratory distress syndrome, infant


Other Names for this Disease

  • Hyaline membrane disease
  • Infantile respiratory distress syndrome
  • IRDS
  • Neonatal respiratory distress syndrome
  • NRDS
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.

Treatment

Medical Products

The medication(s) listed in the table(s) below have been approved by the Food and Drug Administration (FDA) for treatment of this condition. The FDA Office of Orphan Products Development designates "orphan products" for those that treat rare diseases affecting fewer than 200,000 Americans. The table(s) below may not be an exhaustive list of drugs or products used to treat this condition. There may be other products available that are not considered orphan products. To search for all FDA approved drugs, visit Drugs@FDA. You can find orphan products used to treat other conditions by searching the Orphan Drug Product Designation database.


Generic Name Pulmonary surfactant replacement, porcine
Trade Name
(Manufacturer Name)
Curosurf®
(Cornerstone Therapeutics Inc.)
Indication
The FDA has approved this product to be used in this manner.
Treatment (rescue) of respiratory distress syndrome in premature infants.
More Information about this product Drug Information Portal

Generic Name Colfosceril palmitate, cetyl alcohol, tyloxapol
Trade Name
(Manufacturer Name)
Exosurf Neonatal for Intratracheal Suspension
(Glaxo Wellcome Inc.)
Indication
The FDA has approved this product to be used in this manner.
Treatment of established hyaline membrane disease at all gestational ages.
More Information about this product Drug Information Portal

Generic Name Surface active extract of saline lavage of bovine lungs
Trade Name
(Manufacturer Name)
Infasurf®
(Forest Laboratories, Inc.)
Indication
The FDA has approved this product to be used in this manner.
Treatment and prevention of respiratory failure due to pulmonary surfactant deficiency in preterm infants.
More Information about this product Drug Information Portal

Generic Name Beractant
Trade Name
(Manufacturer Name)
Survanta intratracheal suspension
(Abbott)
Indication
The FDA has approved this product to be used in this manner.
Treatment of ("rescue") of premature infants with RDS confirmed by x-ray and requiring mechanical ventilation.
More Information about this product Drug Information Portal

Other Names for this Disease
  • Hyaline membrane disease
  • Infantile respiratory distress syndrome
  • IRDS
  • Neonatal respiratory distress syndrome
  • NRDS
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.